AU6767300A - Cancer treatments and diagnostics utilizing rad51 related molecules and methods - Google Patents

Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Info

Publication number
AU6767300A
AU6767300A AU67673/00A AU6767300A AU6767300A AU 6767300 A AU6767300 A AU 6767300A AU 67673/00 A AU67673/00 A AU 67673/00A AU 6767300 A AU6767300 A AU 6767300A AU 6767300 A AU6767300 A AU 6767300A
Authority
AU
Australia
Prior art keywords
methods
related molecules
cancer treatments
rad51
diagnostics utilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67673/00A
Inventor
Gurucharan Reddy
Horst-Werner Sturzbecher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pangene Corp
Original Assignee
Pangene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/454,495 external-priority patent/US6576759B2/en
Application filed by Pangene Corp filed Critical Pangene Corp
Publication of AU6767300A publication Critical patent/AU6767300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU67673/00A 1999-08-10 2000-08-10 Cancer treatments and diagnostics utilizing rad51 related molecules and methods Abandoned AU6767300A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US14809299P 1999-08-10 1999-08-10
US14809199P 1999-08-10 1999-08-10
US60148091 1999-08-10
US60148092 1999-08-10
US15461699P 1999-09-17 1999-09-17
US60154616 1999-09-17
US45530099A 1999-12-06 1999-12-06
US09455300 1999-12-06
US09/454,495 US6576759B2 (en) 1999-02-10 1999-12-06 Antisense inhibition of RAD51
US09454495 1999-12-06
PCT/US2000/022077 WO2001011369A1 (en) 1999-08-10 2000-08-10 Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Publications (1)

Publication Number Publication Date
AU6767300A true AU6767300A (en) 2001-03-05

Family

ID=27538317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67673/00A Abandoned AU6767300A (en) 1999-08-10 2000-08-10 Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Country Status (5)

Country Link
EP (1) EP1204868A1 (en)
JP (1) JP2003506100A (en)
AU (1) AU6767300A (en)
CA (1) CA2379608A1 (en)
WO (1) WO2001011369A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013488A2 (en) * 2001-08-09 2003-02-20 Pangene Corporation Methods and compositions for inhibiting rad51
ES2529147T3 (en) * 2006-12-26 2015-02-17 Pharmacyclics, Inc. Method for using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
WO2008156827A2 (en) * 2007-06-20 2008-12-24 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular grading methods for ductal carcinoma in situ
US8188252B2 (en) * 2008-11-17 2012-05-29 University Of Rochester Rad51 derived cancer cell specific promoters for targeted anti-cancer therapy
UA110853C2 (en) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Dosage forms histone deacetylase inhibitor in combination with bendamustine and their use
US9393250B2 (en) 2012-04-12 2016-07-19 University Of Saskatchewan Phthalocyanine compounds useful as RecA inhibitors and methods of using same
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51

Also Published As

Publication number Publication date
JP2003506100A (en) 2003-02-18
CA2379608A1 (en) 2001-02-15
EP1204868A1 (en) 2002-05-15
WO2001011369A1 (en) 2001-02-15
WO2001011369A8 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
AU8026600A (en) Brachytherapy instrument and methods
AU2001290891A1 (en) Frameless radiosurgery treatment system and method
AU6528800A (en) Methods and apparatuses for radiation treatment
AU3729400A (en) Medical grafting methods and apparatus
AU1808101A (en) Medical grafting methods and apparatus
AU2373200A (en) Apparatuses and methods for forming assemblies
AU4052897A (en) Cancer treatment method
AU5788300A (en) Medical treatment method and kit
AU2002237774A1 (en) Latch apparatus and method
AU1250401A (en) Door construction and method
AUPQ155799A0 (en) Therapeutic methods and uses
AU7119100A (en) Stereotactic apparatus and methods
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU5317500A (en) Medical grafting apparatus and methods
AU2002328235A1 (en) Process management and process validation
AU6767300A (en) Cancer treatments and diagnostics utilizing rad51 related molecules and methods
AU7856100A (en) Methods for treating solid tumors with irradiation and bacteria
AU2002227247A1 (en) Biofilm therapy process and elements
AU6385600A (en) Interconnect assemblies and methods
AU1083501A (en) Antibiotic-metal complex and methods
AU7491700A (en) Shopping list organizer apparatus and method
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2002305138A1 (en) Methods and materials for cancer treatment
AU5316099A (en) Prostate cancer assays and related methods
AU2616201A (en) Cancer treatment method

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase